BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

354 related articles for article (PubMed ID: 31787543)

  • 1. Preoperative Plasma Fibrinogen and D-dimer as Prognostic Biomarkers for Non-Muscle-Invasive Bladder Cancer.
    Li X; Shu K; Zhou J; Yu Q; Cui S; Liu J; Zhou R; Ding D
    Clin Genitourin Cancer; 2020 Feb; 18(1):11-19.e1. PubMed ID: 31787543
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognostic value of modified Glasgow Prognostic Score in non-muscle-invasive bladder cancer.
    Kimura S; D' Andrea D; Soria F; Foerster B; Abufaraj M; Vartolomei MD; Iwata T; Karakiewicz PI; Rink M; Gust KM; Egawa S; Shariat SF
    Urol Oncol; 2019 Mar; 37(3):179.e19-179.e28. PubMed ID: 30580906
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prognostic value of fibrinogen and D-dimer-fibrinogen ratio in resectable gastrointestinal stromal tumors.
    Cai HX; Li XQ; Wang SF
    World J Gastroenterol; 2018 Nov; 24(44):5046-5056. PubMed ID: 30510379
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic Value of Serum Cholinesterase in Non-muscle-invasive Bladder Cancer.
    Kimura S; Soria F; D'Andrea D; Foerster B; Abufaraj M; Vartolomei MD; Karakiewicz PI; Mathieu R; Moschini M; Rink M; Egawa S; Shariat SF; Gust KM
    Clin Genitourin Cancer; 2018 Dec; 16(6):e1123-e1132. PubMed ID: 30061034
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of substratification on predicting oncological outcomes in patients with primary high-risk non-muscle-invasive bladder cancer who underwent transurethral resection of bladder tumor.
    Fujita N; Hatakeyama S; Momota M; Tobisawa Y; Yoneyama T; Yamamoto H; Imai A; Ito H; Yoneyama T; Hashimoto Y; Yoshikawa K; Ohyama C
    Urol Oncol; 2020 Oct; 38(10):795.e9-795.e17. PubMed ID: 32417111
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Increased preoperative levels of plasma fibrinogen and D dimer in patients with renal cell carcinoma is associated with poor survival and adverse tumor characteristics.
    Erdem S; Amasyali AS; Aytac O; Onem K; Issever H; Sanli O
    Urol Oncol; 2014 Oct; 32(7):1031-40. PubMed ID: 25027687
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Preoperative aspartate transaminase/alanine transaminase ratio as a prognostic biomarker in primary non-muscle-invasive bladder cancer: a propensity score-matched study.
    Cheng X; Zhou X; Yi M; Xu S; Zhang C; Wang G
    BMC Urol; 2021 Sep; 21(1):136. PubMed ID: 34579695
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic Impact of Preoperative Plasma Levels of Urokinase Plasminogen Activator Proteins on Disease Outcomes after Radical Cystectomy.
    Schuettfort VM; Pradere B; D'Andrea D; Grossmann NC; Quhal F; Mostafaei H; Laukhtina E; Mori K; Rink M; Karakiewicz PI; Motlagh RS; Katayama S; Lotan Y; Scherr D; Abufaraj M; Fajkovica H; Compérat E; Enikeev D; Shariat SF
    J Urol; 2021 Nov; 206(5):1122-1131. PubMed ID: 34181469
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pathology in repeated transurethral resection of a bladder tumor as a risk factor for prognosis of high-risk non-muscle-invasive bladder cancer.
    Tae BS; Jeong CW; Kwak C; Kim HH; Moon KC; Ku JH
    PLoS One; 2017; 12(12):e0189354. PubMed ID: 29244843
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pretreatment plasma D-dimer, fibrinogen, and platelet levels significantly impact prognosis in patients with epithelial ovarian cancer independently of venous thromboembolism.
    Man YN; Wang YN; Hao J; Liu X; Liu C; Zhu C; Wu XZ
    Int J Gynecol Cancer; 2015 Jan; 25(1):24-32. PubMed ID: 25347092
    [TBL] [Abstract][Full Text] [Related]  

  • 11. High aurora kinase expression identifies patients with muscle-invasive bladder cancer who have poor survival after neoadjuvant chemotherapy.
    Burgess EF; Livasy C; Trufan S; Hartman A; Guerreri R; Naso C; Clark PE; Grigg C; Symanowski J; Raghavan D
    Urol Oncol; 2019 Dec; 37(12):900-906. PubMed ID: 31597600
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Preoperative neutrophil-lymphocyte ratio can significantly predict mortality outcomes in patients with non-muscle invasive bladder cancer undergoing transurethral resection of bladder tumor.
    Kang M; Jeong CW; Kwak C; Kim HH; Ku JH
    Oncotarget; 2017 Feb; 8(8):12891-12901. PubMed ID: 28039452
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The prognostic value of routine preoperative blood parameters in muscle-invasive bladder cancer.
    Zhang J; Zhou X; Ding H; Wang L; Liu S; Liu Y; Chen Z
    BMC Urol; 2020 Mar; 20(1):31. PubMed ID: 32192483
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Absence of Tumor on Repeat Transurethral Resection of Bladder Tumor Does Not Predict Final Pathologic T0 Stage in Bladder Cancer Treated with Radical Cystectomy.
    Kukreja JB; Porten S; Golla V; Ho PL; Noguera-Gonzalez G; Navai N; Kamat AM; Dinney CPN; Shah JB
    Eur Urol Focus; 2018 Sep; 4(5):720-724. PubMed ID: 28753837
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Prognostic associations of preoperative plasma levels of fibrinogen and D-dimer after curative resection in patients with colorectal cancer].
    Wang JF; Guo Z; Tang L; Guo JS; Hu J; Liu JZ
    Zhonghua Yi Xue Za Zhi; 2013 Mar; 93(12):906-9. PubMed ID: 23863674
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Preoperative anemia is associated with disease recurrence and progression in patients with non-muscle-invasive bladder cancer.
    Soria F; Moschini M; Abufaraj M; Wirth GJ; Foerster B; Gust KM; Özsoy M; Briganti A; Gontero P; Mathieu R; Rouprêt M; Karakiewicz PI; Shariat SF
    Urol Oncol; 2017 Mar; 35(3):113.e9-113.e14. PubMed ID: 27908681
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic and clinicopathologic value of ki-67 and profilin 1 immunohistochemical expression in primary pT1 urothelial bladder cancer.
    Culpan M; Turan T; Ozkanli SS; Zenginkinet T; Kazan O; Ucar T; Atis G; Caskurlu T; Yildirim A
    J Cancer Res Ther; 2021; 17(2):434-442. PubMed ID: 34121689
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Androgen receptor mRNA expression is a predictor for recurrence-free survival in non-muscle invasive bladder cancer.
    Yasui M; Kawahara T; Izumi K; Yao M; Ishiguro Y; Ishiguro H; Uemura H; Miyoshi Y
    BMC Cancer; 2019 Apr; 19(1):331. PubMed ID: 30961575
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cell-cycle markers do not improve discrimination of EORTC and CUETO risk models in predicting recurrence and progression of non-muscle-invasive high-grade bladder cancer.
    Passoni N; Gayed B; Kapur P; Sagalowsky AI; Shariat SF; Lotan Y
    Urol Oncol; 2016 Nov; 34(11):485.e7-485.e14. PubMed ID: 27637323
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Expression and prognostic utility of PD-L1 in patients with squamous cell carcinoma of the bladder.
    Owyong M; Lotan Y; Kapur P; Panwar V; McKenzie T; Lee TK; Zi X; Martin JW; Mosbah A; Abol-Enein H; Ghoneim M; Youssef RF
    Urol Oncol; 2019 Jul; 37(7):478-484. PubMed ID: 30910351
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.